New drug duo aims to outsmart resistant lung cancer

NCT ID NCT03778229

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a second drug, savolitinib, to a standard lung cancer drug, osimertinib, can help control cancer that has started growing again. It is for adults with a specific type of advanced non-small cell lung cancer whose disease progressed after initial treatment with osimertinib alone. The goal is to see if this combination can shrink tumors and delay cancer growth for a longer period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Los Angeles, California, 90024, United States
Research Site

Sacramento, California, 95817, United States
Research Site

Washington D.C., District of Columbia, 20016, United States
Research Site

Baltimore, Maryland, 21201, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Rochester, Minnesota, 55905, United States
Research Site

Brooklyn, New York, 11220, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Pittsburgh, Pennsylvania, 15232, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Barretos, 14784-400, Brazil
Research Site

Curitiba, 80810-050, Brazil
Research Site

Goiânia, 74093-300, Brazil
Research Site

Porto Alegre, 90540-140, Brazil
Research Site

Porto Alegre, 90610-000, Brazil
Research Site

Rio de Janeiro, 22271-110, Brazil
Research Site

Salvador, 41950-640, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

São Paulo, 01509-900, Brazil
Research Site

Calgary, Alberta, T2N 5G2, Canada
Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Newmarket, Ontario, L3Y 2P9, Canada
Research Site

North York, Ontario, M2K 1E1, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Santiago, 7500713, Chile
Research Site

Santiago, 7520349, Chile
Research Site

Santiago, 8420383, Chile
Research Site

Aalborg, 9100, Denmark
Research Site

Herlev, 2730, Denmark
Research Site

København Ø, 2100, Denmark
Research Site

Næstved, 4700, Denmark
Research Site

Odense, 5000, Denmark
Research Site

Vejle, 7100, Denmark
Research Site

Dijon, 21079, France
Research Site

Marseille, 13915, France
Research Site

Nantes, 44093, France
Research Site

Paris, 75020, France
Research Site

Paris, 75248, France
Research Site

Rennes, 35033, France
Research Site

Bangalore, 560064, India
Research Site

Chennai, 600035, India
Research Site

Kolkata, 700160, India
Research Site

New Delhi, 110085, India
Research Site

Avellino, 83100, Italy
Research Site

Florence, 50134, Italy
Research Site

Milan, 20133, Italy
Research Site

Milan, 20141, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Padua, 35128, Italy
Research Site

Parma, 43126, Italy
Research Site

Perugia, 06132, Italy
Research Site

Peschiera del Garda, 37019, Italy
Research Site

Fukuoka, 812-8582, Japan
Research Site

Hiroshima, 730-8518, Japan
Research Site

Kanazawa, 920-8641, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Niigata, 951-8566, Japan
Research Site

Sapporo, 003-0804, Japan
Research Site

Sayama, 589-8511, Japan
Research Site

Sunto-gun, 411-8777, Japan
Research Site

Wakayama, 641-8510, Japan
Research Site

Yokohama, 241-0815, Japan
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Suwon, 16247, South Korea
Research Site

Córdoba, 14004, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28046, Spain
Research Site

Málaga, 29010, Spain
Research Site

Valencia, 46026, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Hsinchu, 300, Taiwan
Research Site

Kaohsiung City, 83301, Taiwan
Research Site

New Taipei City, 23561, Taiwan
Research Site

Taichung, 402, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taoyuan District, 333, Taiwan
Research Site

Hà Nội, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

CARCINOMA